|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In particular, class 4-6 semaphorins and axonal guidance cues endowed with pro-tumorigenic activity were more expressed in TAF15-NR4A3 tumors; vice versa, class 3 semaphorins, considered to convey growth inhibitory signals, were more abundant in EWSR1-NR4A3 EMC.
|
31020999 |
2019 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Specific cytogenetic alterations involving the NR4A3 gene are found in EMC and can be identified in FNA samples.
|
30353688 |
2018 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings expand the spectrum of NR4A3 fusion partners involved in EMC pathobiology.
|
28383167 |
2017 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft tissue sarcoma, marked by NR4A3 rearrangement.
|
24703573 |
2014 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Extraskeletal myxoid chondrosarcoma is characterized by the reciprocal chromosomal translocation t(9;22) and the resultant fused gene EWS RNA-binding protein 1 and nuclear receptor subfamily 4, group A, member 3 (EWSR1-NR4A3).
|
24508382 |
2014 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings show that a fusion product of FUS and NR4A3 may be an additional pathway to development of EMC.
|
25130955 |
2014 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Extraskeletal myxoid chondrosarcoma (EMC) is a rare mesenchymal neoplasm with a characteristic translocation usually involving NR4A3 and EWSR1.
|
23588370 |
2013 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We have performed microarray analyses of these cells and identified several genes overexpressed in the presence of EWS/NR4A3 which are also overexpressed in EMC tumors.
|
22592656 |
2012 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
NR4A3 rearrangement reliably distinguishes between the clinicopathologically overlapping entities myoepithelial carcinoma of soft tissue and cellular extraskeletal myxoid chondrosarcoma.
|
22569967 |
2012 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This is the first reported case of a remarkable soft tissue sarcoma that exhibits overlapping morphologic features between SS and EMC and that also harbors a combination of SS18-SSX2 and EWS-NR4A3 gene fusions.
|
22743288 |
2012 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Most, although not all, examples of EMC possess a unique balanced chromosomal translocation [t(9;22)(q22;q12)] between the EWSR1 and NR4A3 (previously termed TEC) genes.
|
22804337 |
2012 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that the overall expression of PPARG in EMC may be regulated in part by the balance between EWSR1/NR4A3 and NR4A3, and that PPARG may play a crucial role in the development of these tumours.
|
18855877 |
2009 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
FusionGene
|
disease |
ORPHANET |
These results suggest that the overall expression of PPARG in EMC may be regulated in part by the balance between EWSR1/NR4A3 and NR4A3, and that PPARG may play a crucial role in the development of these tumours.
|
18855877 |
2009 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Distinct chromosomal translocations have been identified in several myxoid sarcomas, including t(12;16)(q13;p11) FUS-DDIT3 in myxoid liposarcoma, t(7;16)(q34;p11) FUS-CREB3L2 in low-grade fibromyxoid sarcoma, and t(9;22)(q31;q12) EWSR1-NR4A3 in extraskeletal myxoid chondrosarcoma.
|
18162764 |
2008 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Chromosomal rearrangements involving 9q22, such as t(9;22)(q22;q12), and resultant NR4A3 fusion genes are tumor-type specific or pathognomotic for this entity and are assumed to play an important role in the development of EMC.
|
15998372 |
2005 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Several observations suggest that one role of EWS/NOR1 in EMC may be to deregulate the expression of specific genes involved in the tumoral process.
|
16112421 |
2005 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest that aberrant coexpression of NOR1 and SIX3 is a potential alternative mechanism underlying the development of EMC.
|
15262426 |
2004 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
TFG/NOR1 fusion appears to play an oncogenic role equivalent to those of other NOR1 fusions in EMC.
|
15188455 |
2004 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results support the hypothesis that the role of EWS/NOR-1 in EMC may be to disrupt the proliferation properties of cells involved in chondrogenesis.
|
15212958 |
2004 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Molecular genetic analysis revealed a TAF15/NR4A3 fusion, a characteristic rearrangement occurring in about 25% of cytogenetically investigated EMC.
|
14708728 |
2004 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
NOR-1 is normally involved in the balance between cell proliferation and cell death, and is implicated in oncogenesis as part of the EWS/NOR-1 fusion protein found in human extraskeletal myxoid chondrosarcoma (EMC) tumors.
|
12543801 |
2003 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Molecular genetic characterization of the EWS/CHN and RBP56/CHN fusion genes in extraskeletal myxoid chondrosarcoma.
|
12378528 |
2002 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, RT-PCR detection of EWS-CHN or TAF2N-CHN fusion gene using archival paraffin-embedded tissue is a feasible and useful ancillary technique for the diagnosis of EMCS.
|
11679947 |
2001 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genetic investigations showed the recently described novel translocation t(9;17)(q22;q11.2) and associated fusion of the CHN and RBP56 genes, contrasting with the translocation t(9;22)(q22;q12) and EWS/CHN gene fusion found in the majority of EMCs.
|
10895826 |
2000 |
|
Extraskeletal Myxoid Chondrosarcoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Identification of a novel fusion gene involving hTAFII68 and CHN from a t(9;17)(q22;q11.2) translocation in an extraskeletal myxoid chondrosarcoma.
|
10602520 |
1999 |